dsdsa

product

Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

continue on to further improve, to make sure product top quality in line with market and consumer standard requirements. Our firm has a excellent assurance program have already been established for Improving Sleep Melatonine, Docetaxel, Dapoxetine Hcl Powder, Our company is working through the procedure principle of "integrity-based, cooperation created, people oriented, win-win cooperation". We hope we can have a pleasant relationship with businessman from all around the earth.
Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai Detail:

Product name Bimatoprost
Synonyms (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
CAS No. 155206-00-1
Appearance White or almost white powder
Molecular Formula C25H37NO4
Molecular Weight 415.57
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Bimatoprost Cas:155206-00-1

ITEMS STANDARDS RESULTS
Appearance White or almost white powder Complies
Identification NMR: Both spectrum of the test sample and the reference standard exhibit the sameintensity of absorption at the same wave

number.

Complies
Optical rotation [α]20D: +33.0°~+37.0°( c=1.0,CH3CN) 35.6°
Water N.M.T.1.0 % 0.18%
Related Substances 5,6-trans-Bimatoprost and 15-keto-Bimatoprost:N.M.T. 0.2 %

Any other unknown impurities: N.M.T. 0.10 %

Total impurities: N.M.T. 1.0%

Not detected0.08%

0.15%

Residual Solvents Ethanol: N.M.T. 0.50%Tert-Butyl methyl ether: N.M.T. 0.50%

Ethyl acetate: N.M.T. 0.50%

Not detectedNot detected

0.13%

Purity (HPLC) N.L.T 99.0 % 99.85%
Conclusion

It meets the requirements

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai detail pictures

Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai detail pictures

Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai detail pictures


Related Product Guide:

With our superb management, potent technical capability and strict quality command procedure, we go on to provide our shoppers with trustworthy high-quality, reasonable costs and outstanding services. We goal at becoming considered one of your most trustworthy partners and earning your pleasure for Manufacturer of Tofacitinib Citrate Api - 99% 155206-00-1 Bimatoprost for Treatment of Glaucoma and Eyelashes Growth – Yibai , The product will supply to all over the world, such as: Miami, Panama, Luxembourg, Each product is carefully made, it will make you satisfied. Our products in the production process have got strictly monitored, because it is only to provide you the best quality, we will feel confident. High production costs but low prices for our long-term cooperation. You can have a variety choices and the value of all types are same reliable. If you have any question, do not hesitate to ask us.
  • The company has a good reputation in this industry, and finally it tured out that choose them is a good choice.
    5 Stars By Alexia from Serbia - 2017.06.16 18:23
    We are old friends, the company's product quality has been always very good and this time the price is also very cheap.
    5 Stars By King from Greece - 2017.01.11 17:15
    Write your message here and send it to us